INTRODUCTION {#s1}
============

microRNA (miRNA) is a small non-coding RNA molecule (containing about 22 nucleotides) that silences cognate target genes *via* base-pairing with complementary sequences within 3′UTRs (sometimes 5′UTRs or coding regions) in corresponding mRNAs, resulting in inhibition of translation or mRNA degradation \[[@R1]\]. miRNA is involved in various biological processes, including cell proliferation, apoptosis, metabolism and differentiation. miR-183-96-182 cluster is a highly conserved miRNA cluster \[[@R2]\]. Members of this cluster are located within a 5-kb region on human chromosome 7q32.2 \[[@R3]\], transcribed in the same direction from telomere to centromere, and have similar biological functions in some of the closely related signaling pathways.

The transcriptional start site (TSS) of miR-183-96-182 cluster has not yet been confirmed. Several studies suggested its localization in the 5207, 5200, or 5068 base upstream of miR-183 precursor \[[@R4]--[@R6]\]. Tang *et al*. have suggested that the potential TSS of miR-183-96-182 cluster maybe localized at the 5112 site upstream domain of miR-96, which contains seven binding domains of β-Catenin/TCF/LEF-1 complex \[[@R7]\]. Additionally, previous reports have indicated that three TGF-β response elements at 11519-9069 region upstream domain of miR-182, can directly interact with Smad2/Smad4 complex \[[@R8]\]. It is known, that many upstream regulators, including HSF2, β-catenin/TCF/LEF-1, TGF-β, SP1, P53, growth hormones, Akt/FOXP3, and MYOD increase the expression of miR-183-96-182 cluster \[[@R3], [@R7]--[@R18]\], while ZEB1, MYCN, HDAC, EVI1, and KLF-3 repress this cluster \[[@R9], [@R19]--[@R22]\]. Hypoxia and/or starvation are known to up-regulate miR-96/miR-182 expression, and miR-183/miR-182 increases the expression of hypoxia inducible factor 1α (HIF-1α) \[[@R23]--[@R27]\]. Thus, the relationship between miR-183-96-182 cluster and hypoxia or starvation still needs to be investigated.

While investigating its regulatory effect on the downstream target genes, the miR-183-96-182 cluster was discovered as being a regulator of tumor development, the nervous system and the immune system \[[@R2], [@R28]--[@R34]\]. Recent studies have documented localization of some tumor-related genes, such as CDK6, BRAF, and c-MET at the upstream/downstream domain of miR-183-96-182 cluster \[[@R23], [@R35], [@R36]\], suggesting that these genes might be regulated to process similar functions of tumor-related molecules. Furthermore, over-expression of miR-183-96-182 cluster has been described in most malignant tumors including, hepatocarcinoma \[[@R37]--[@R39]\], esophageal cancer \[[@R40]\], gastric carcinoma \[[@R7]\], prostate cancer \[[@R41]\], bladder cancer \[[@R42], [@R43]\], upper urinary tract urothelial cancer \[[@R44]\], colon cancer \[[@R45]--[@R47]\], lung cancer \[[@R48]\], breast cancer \[[@R3], [@R49]\], and chronic myeloid leukemia \[[@R50]\], indicating that it may function as an oncogene cluster. In contrast, miR-183-96-182 cluster functions as a tumor-suppressor gene with down-regulation in pancreatic cancer \[[@R51]\] and melanoma \[[@R52]\] have been documented. In addition, some recent studies have reported some contradicting features exhibited by the miR-183-96-182 cluster in gastric carcinoma \[[@R53], [@R54]\] and lung cancer \[[@R55]--[@R58]\].

The available evidence, thus, suggests much variability in the role played by the miR-183-96-182 cluster in tumorigenesis, tumor progression and metastasis. In this review, we profile the dysregulation and functional roles of the miR-183-96-182 cluster during tumorigenesis in various tumor cells, and its prognostic relevance in clinical settings. The outline of this paper is provided in Appendix 1-1.

MATERIALS AND METHODS {#s2}
=====================

In this review, we performed an online search of articles published from January 2000 to March 2016 in Pubmed (<http://www.ncbi.nlm.nih.gov/pubmed>). We used the following query: (miR-96 OR miR96 OR microRNA96 OR miR-183 OR miR183 OR microRNA183 OR miR-182 OR miR182 OR microRNA182 OR miR-183-96-182 OR miR-183/96/182 OR miR-183\~96\~182). Only English language articles were included. A total of 620 records were retrieved. We then reviewed the titles and abstracts, and eliminated duplicate and irrelevant articles. Eventually, 155 full-length articles were included in this review.

RESULTS AND DISCUSSION {#s3}
======================

miR-183-96-182 cluster in cancer cell proliferation {#s3_1}
---------------------------------------------------

### miR-183-96-182 cluster promotes cancer cell proliferation {#s3_1_1}

For examining the role of miR-183-96-182 cluster in cell proliferation, the relation between miR-96 and the members of forkhead box protein (FOX) family has been investigated. FOXO, a subfamily of FOX family that includes FOXO1, FOXO2, FOXO3 and FOXO4, was found to be associated with cell apoptosis. Recent studies have demonstrated that FOXO can activate Bim and p27kip1, resulting in increased cell apoptosis and cell cycle inhibition \[[@R59], [@R60]\]. In 2009, Guttilla *et al.* found coordinated repression of FOXO1 by miR-96, miR-182 and miR-27a in breast cancer cells \[[@R49]\]. Targetscan prediction revealed three members of the FOXO protein family, including FOXO1, FOXO3 and FOXO4 as potential targets of the miR-183-96-182 cluster. However, only FOXO1 and FOXO3 have been confirmed by previous studies \[[@R16], [@R35], [@R49], [@R61]--[@R65]\], in various types of cancers such as, prostate \[[@R63], [@R66], [@R67]\], bladder \[[@R43], [@R68]\], colorectal \[[@R62]\], breast \[[@R69]\], lung \[[@R61]\], lymphoma \[[@R64]\], and endometrial carcinoma \[[@R70]\] (Table [1](#T1){ref-type="table"}). Additionally, recent studies have indicated that miR-182 promotes cell proliferation and tumor invasion by targeting FOXF2 \[[@R71], [@R72]\], a known inhibitor of MMPs and WNT5A \[[@R73], [@R74]\].

###### miR-183-96-182 cluster in cancer cell proliferation

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Member of miR-183-96-182 cluster   Oncogene/Tumor suppressor   Target genes                            Tested in human cancer tissue   Cell lines                                                                           Cancer types                                      Results
  ---------------------------------- --------------------------- --------------------------------------- ------------------------------- ------------------------------------------------------------------------------------ ------------------------------------------------- ---------------------------------------------------------------------
  miR-183-96-182                     Oncogene                    FOXO1                                   \--                             L428                                                                                 Lymphoma                                          Promotes cell proliferation \[[@R64]\].

  miR-183-96-182                     Oncogene                    FGF9, CPEB1, FOXO1                      ✓                               U251, U87                                                                            Glioma                                            Promotes cell growth \[[@R65]\].

  miR-183-96-182                     Oncogene                    RAB21(miR-183)\                                                         MCF-7, T47D                                                                          Breast cancer                                     Promotes cell proliferation \[[@R3]\].
                                                                 RAB40B(miR-96 and miR-183)\                                                                                                                                                                                    
                                                                 TNFSF11(miR-96)                                                                                                                                                                                                

  miR-183-96-182                     Oncogene                    \--                                     ✓                               T24, UM-UC-3                                                                         Bladder Cancer                                    Promotes cell proliferation \[[@R154]\].

  miR-183-96-182                     Oncogene                    \--                                     \--                             R262, R300 UW402, UW426, D341, D384, D425, D458, D556, D283, DAOY                    Medulloblastoma                                   Promote cell proliferation \[[@R155]\].

  miR-96, miR-182                    Oncogene                    FOXO1                                   ✓                               MCF-7, T47D, MDA-MB-231, MDA-MB-435                                                  Breast cancer                                     Promote cell proliferation \[[@R49]\].

  miR-96, miR-182                    Oncogene                    EFNA5                                   ✓                               HepG2, Hep3B, Huh7, SK-Hep1                                                          Hepatocellular carcinoma                          Promote cell proliferation \[[@R85]\].

  miR-96, miR-182                    Tumor suppressor            \-                                      \--                             A375, SK-MEL-28                                                                      Melanoma                                          Inhibit cell proliferation \[[@R52]\]

  miR-183                            Oncogene                    PDCD4                                   ✓                               Eca109, TE13 and EC109, EC9706                                                       Esophageal cancer                                 Promote cell proliferation \[[@R76], [@R81]\].

  miR-183                            Oncogene                    PDCD4                                   ✓                               SGC-7901                                                                             Gastric cancer\*                                  Promote cell proliferation \[[@R78]\].

  miR-183                            Oncogene                    NEFL                                    ✓                               U251                                                                                 Glioma                                            Promote cell proliferation \[[@R156]\].

  miR-183                            Oncogene                    PDCD4                                   ✓                               HepG2, Huh7                                                                          Hepatocellular carcinoma                          Promote cell proliferation \[[@R79]\].

  miR-183                            Oncogene                    PDCD4                                   \--                             SW1990                                                                               Pancreatic cancer                                 Promote cell proliferation \[[@R80]\].

  miR-183                            Oncogene                    SOCS-6                                  ✓                               PANC-1                                                                               Pancreatic cancer                                 Promote cell proliferation \[[@R157]\].

  miR-183                            Oncogene                    SOCS-6                                  ✓                               HepG2, Hep3B                                                                         Hepatocellular carcinoma                          Promote cell proliferation \[[@R158]\].

  miR-183                            Oncogene                    PP2A-Cα, PP2A-Cβ, PP2A-B56-γ            ✓                               ACHN, A498                                                                           Renal cancer                                      Promote cell proliferation \[[@R104]\].

  miR-183                            Oncogene                    DKK-3, SMAD4                            ✓                               PC-3, DU-145, LNCaP                                                                  Prostate cancer                                   Promote cell proliferation \[[@R159]\].

  miR-183                            Tumor suppressor            BMI1                                    ✓                               AGS, SGC7901, MKN28, MGC803, HGC27                                                   Gastric cancer\*                                  Inhibit cell proliferation \[[@R103]\].

  miR-96                             Oncogene                    FOXO1                                   ✓                               HEC-1B                                                                               Endometrial cancer.                               Promote cell proliferation \[[@R70]\].

  miR-96                             Oncogene                    FOXO1                                   \--                             HepG2                                                                                Hepatocellular carcinoma                          Promote cell proliferation \[[@R160]\].

  miR-96                             Oncogene                    FOXO1                                   ✓                               T24                                                                                  Bladder cancer                                    Promote cell proliferation \[[@R68]\].

  miR-96                             Oncogene                    FOXO1                                   ✓                               PC3, LNCaP, and LNCaP, DU-145, PC3, 22rv-1, and 22Rv1, LNCaP clone FGC, DU145, PC3   Prostate cancer\*\*                               Promote cell proliferation \[[@R63], [@R66], [@R67]\].

  miR-96                             Oncogene                    FOXO1                                   ✓                               SW480, SW620                                                                         Colorectal cancer                                 Promote cell proliferation \[[@R62]\].

  miR-96                             Oncogene                    FOXO3                                   \--                             HepG2                                                                                Hepatocellular carcinoma                          Promote cell proliferation \[[@R160]\].

  miR-96                             Oncogene                    FOXO3                                   ✓                               SW480, SW620                                                                         Colorectal cancer                                 Promote cell proliferation \[[@R62]\].

  miR-96                             Oncogene                    FOXO3                                   ✓                               MCF-7, ZR-75-30, BT549, Bcap37, MDA-MB435, SKBR3, MDA-MB453, T47D                    Breast cancer                                     Promote cell proliferation \[[@R69]\].

  miR-96                             Oncogene                    FOXO3                                   ✓                               A549, SPC-A-1                                                                        Lung cancer\*\*\*                                 Promote cell proliferation \[[@R61]\].

  miR-96                             Oncogene                    RECK                                    ✓                               MDA-MB-231, MCF-7, MDA-MB-468, MDA-MB-435, T-74D, MDA-MB-453                         Breast cancer                                     Promote cell proliferation \[[@R83]\].

  miR-96                             Oncogene                    RECK                                    ✓                               A549, SK-MES-1, H1299                                                                Lung cancer\*\*\*                                 Promote cell proliferation \[[@R84]\].

  miR-96                             Oncogene                    HBP1                                    ✓                               U-87 MG, U-251 MG, U-373 MG, M059J                                                   Glioma                                            Promote cell proliferation \[[@R75]\].

  miR-96                             Oncogene                    MTOR                                    ✓                               LNCaP, 22Rv-1                                                                        Prostate cancer                                   Promote cell proliferation (Under hypoxia) \[[@R23]\].

  miR-96                             Tumor suppressor            KRAS                                    ✓                               HPDE, BxPC-3, PK-8, and MIA PaCa-2, PANC-1, BxPC-3                                   Pancreatic cancer                                 Inhibit cell proliferation \[[@R20], [@R51]\].

  miR-96                             Tumor suppressor            HERG1                                   ✓                               PANC-1, SW1990, CFPAC-1, HPAC, BxPC-3                                                Pancreatic cancer                                 Inhibit cell proliferation \[[@R89]\].

  miR-96                             Tumor suppressor            GPC1                                    ✓                               Panc-1, AsPC-1, BxPC-3                                                               Pancreatic cancer                                 Inhibit cell proliferation \[[@R90]\].

  miR-96                             Tumor suppressor            ALK                                     ✓                               Karpas 299, SUP-M2, SU-DHL-1, SR-786, DEL, SH-SY5Y, H2228                            Lymphoma, Neuroblastoma, and lung \*\*\* cancer   Inhibit cell proliferation \[[@R88]\].

  miR-96                             Tumor suppressor            ATG7                                    ✓                               LNCaP, 22rv-1                                                                        Prostate cancer\*\*                               Inhibit cell proliferation (Under hypoxia) \[[@R23]\].

  miR-96                             Tumor suppressor            REV1, RAD51                             \--                             U2OS, HeLa, HCC1937, MDA-MB-231, HCT116, PEO1, PEO1 C4-2                             Multiple tumors                                   Sensitize cancer cells to cisplatin and PARP inhibition \[[@R36]\].

  miR-182                            Oncogene                    PDCD4                                   \--                             A549, SPC-A-1 and A549                                                               Lung cancer\*\*\*\*                               Promote cell proliferation \[[@R55], [@R56]\].

  miR-182                            Oncogene                    PDCD4                                   ✓                               OVCAR3, SKOV3, OV2008, HEY, 3AO, A2780, HO8910, C13                                  Ovarian cancer                                    Promote cell proliferation \[[@R77]\].

  miR-182                            Oncogene                    CHL1                                    ✓                               TPC-1, BCPAP                                                                         Papillary thyroid carcinoma                       Promote cell proliferation \[[@R161]\].

  miR-182                            Oncogene                    SATB2                                   ✓                               DLD-1, HCT116, SW480, SW620, Lovo                                                    Colorectal cancer                                 Promote cell proliferation \[[@R162]\].

  miR-182                            Oncogene                    FOXF2                                   ✓                               HT29, SW480, SW620, HCT116                                                           Colorectal cancer                                 Promote cell proliferation \[[@R71]\].

  miR-182                            Oncogene                    \-                                      ✓                               HCT116, HT29, SW480                                                                  Colon cancer                                      Promote cell proliferation \[[@R163]\].

  miR-182                            Oncogene                    CEBPA                                   ✓                               \--                                                                                  Hepatocellular carcinoma                          Promote cell proliferation \[[@R164]\].

  miR-182                            Oncogene                    TP53INP1                                ✓                               HEK293, HepG2                                                                        Hepatocellular carcinoma                          Promote cell proliferation \[[@R86]\].

  miR-182                            Oncogene                    LRRC4                                   ✓                               U251, SF126, SF767                                                                   Glioma                                            Promote cell proliferation \[[@R165]\].

  miR-182                            Oncogene                    TCEAL7                                  \--                             HEC-1B, RL95-2, AN3CA                                                                Endometrial carcinoma                             Promote cell proliferation \[[@R166]\].

  miR-182                            Oncogene                    CUL5                                    ✓                               Ishikawa H                                                                           Endometrial carcinoma                             Promote cell proliferation \[[@R167]\].

  miR-182                            Oncogene                    NDRG1                                   ✓                               LNCap, PC-3, DU145, 22Rv1                                                            Prostate cancer\*\*\*\*\*\*                       Promote cell proliferation \[[@R126]\].

  miR-182                            Oncogene                    FOXF2, RECK, MTSS1                      ✓                               LNCaP, PC-3, DU145                                                                   Prostate cancer\*\*\*\*\*\*                       Promote cell proliferation \[[@R72]\].

  miR-182                            Oncogene                    PFN1                                    ✓                               MDA-MB-231                                                                           Breast cancer                                     Promote cell proliferation \[[@R168]\].

  miR-182                            Oncogene                    RECK, Smad4                             ✓                               J82, T24, UM-UC-3                                                                    Bladder cancer                                    Promote cell proliferation \[[@R169]\].

  miR-182                            Oncogene                    FOXO3                                   \--                             A549, H1299, CL 1-0, CL 1-5                                                          Lung cancer\*\*\*\*                               Promote cell proliferation \[[@R16]\].

  miR-182                            Tumor suppressor            RAD51                                   \--                             OCI-AML3, MV4-11                                                                     Acute myelogenous leukemia.                       Sensitize cancer cells to sapacitabine \[[@R21]\].

  miR-182                            Tumor suppressor            MITF, BCL2, cyclin D2                   \--                             M23, SP6.5                                                                           Posterior uveal melanoma                          Inhibit cell proliferation \[[@R102]\].

  miR-182                            Tumor suppressor            RGS17                                   \--                             CRL-5803, CRL-5889, H2126                                                            Lung cancer\*\*\*\*                               Inhibit cell proliferation \[[@R57]\].

  miR-182                            Tumor suppressor            RASA1                                   ✓(highly expressed in tumor)    Failed to get to the data                                                            Lung squamous cell carcinoma                      Inhibit cell proliferation \[[@R58]\].

  miR-182                            Tumor suppressor            CTTN                                    \--                             A549                                                                                 Lung cancer\*\*\*\*                               Inhibit cell proliferation \[[@R153]\].

  miR-182                            Tumor suppressor            ANUBL1                                  ✓                               SGC-7901                                                                             Gastric cancer                                    Inhibit cell proliferation \[[@R170]\].

  miR-182                            Tumor suppressor            CREB1                                   ✓                               MGC-803, BGC-823, SGC-7901                                                           Gastric cancer                                    Inhibit cell proliferation \[[@R53]\].

  miR-182                            Tumor suppressor            FLOT1                                   ✓                               786-O, Caki-1                                                                        Renal cell carcinoma                              Inhibit cell proliferation \[[@R101]\].

  miR-182                            Tumor suppressor            BCL2, P21(Not biologically validated)   \--                             PC3, LNCaP                                                                           Prostate cancer\*\*\*\*\*\*                       Inhibit cell proliferation \[[@R25]\].
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Contradictory findings were marked as the same number of \*.

Abbreviations: ALK: Anaplastic lymphoma kinase; ANUBL1: Zinc finger, AN1-type domain 4; ATG7: Autophagy related 7; BCL2: B-cell CLL/lymphoma 2; BMI1: BMI1 proto-oncogene; BRCA1: Breast cancer 1 (BRCA1); CEBPA: CCAAT/enhancer binding protein (C/EBP), alpha; CHL1: Cell adhesion molecule L1-like; CREB1: cAMP-responsive element binding protein 1; CTTN: Cortactin; CUL5: Cullin-5; DAP12: DNAX activating protein 12 kDa; DKK-3: Dickkopf homolog-3; EFNA5: EphrinA5, FOXO: Forkhead box O; FOXF2: Forkhead box F2; FGF9: Fibroblast growth factor 9; GPC1: Glypican 1; HBP1: HMG-box transcription factor 1; HERG1: Human ether-a-go-go-related potassium channel; IDH2: Isocitrate dehydrogenase 2; KRAS: Kirsten rat sarcoma viral oncogene homolog; LRRC4: Leucine rich repeat containing 4; MITF: Microphthalmia-associated transcription factor; MTOR: Mechanistic target of rapamycin; MTSS1: Metastasis suppressor 1; NDRG1: N-myc downstream regulated 1; NDRG1: N-myc downstream regulated gene 1; P21: Cyclin-dependent kinase inhibitor 1A; PDCD4: Programmed cell death 4; PFN1: Profilin 1; PP2A: Protein phosphatase 2A; RASA1: RAS p21 GTPase activating protein 1; RECK: Reversion-inducing-cysteine-rich protein with kazal motifs; RAB: Ras-related gtp-binding protein, alternative splice; RAD51: RAD51 recombinase; REV1: REV1, polymerase; RGS17: Regulator of G-protein signaling 17; SATB2: SATB homeobox 2; SMAD4: SMAD family member 4; TCEAL7: Transcription elongation factor A-like 7; TNFSF11: Tumor necrosis factor (ligand) superfamily, member 11; TP53INP1: Tumor protein p53 inducible nuclear protein 1.

HMG-box transcription factor 1 (HBP-1), the target gene of miR-96, has been shown to inhibit Wnt/β-Catenin signaling pathway, and suppress cell proliferation and survival. Thus, miR-96 appears to promote tumor cell growth by down-regulation of HBP-1 in glioma cells \[[@R75]\]. Furthermore, the activation of β-Catenin/TCF/LEF-1 signaling pathway, which is stimulated by knock-down of glycogen synthase kinase 3 beta (GSK3β) \[[@R7]\], is known to induce up-regulation of miR-96 expression \[[@R7], [@R13]\]. As a serine/threonine protein kinase, GSK3β is essential for NF-κB-mediated anti-apoptotic response. Knock-down of GSK3β expression induces up-regulation of β-Catenin/TCF/LEF-1 complex, which binds to the promoter of miR-183-96-182 cluster and stimulates its transcription. Thus, up-regulation of the miR-183-96-182 cluster *via* GSK3β-mediated β-Catenin/TCF/LEF-1 signaling pathway can promote abnormal cell proliferation in gastric cancer \[[@R7]\]. The schematic diagram is provided in Appendix 1-2.

Previous studies have revealed that miR-183 and miR-182 promote cell proliferation, tumor invasion, and chemo-resistance by inhibition of programmed cell death 4 (PDCD4) in various cancer cells \[[@R55], [@R56], [@R76]--[@R81]\]. As a typical tumor suppressor gene (TSG), PDCD4 can inhibit eukaryotic translation initiation factor 4A1 (EIF4A1) and NF-κB-dependent transcriptional factors *via* direct interaction with p65, to induce apoptosis in glioblastoma cells \[[@R82]\]. The PDCD4-targeted inhibition by the miR-183-96-182 cluster, described in various cancers, is summarized in Table [1](#T1){ref-type="table"}. Notably, miR-96 has also been found to inhibit the TSG RECK \[[@R40], [@R83], [@R84]\] and EFNA5 \[[@R85]\]. Besides, miR-96 and miR-182 were found to have an inhibitory effect on TP53INP1 expression \[[@R62], [@R86]\]. Collectively, the available evidence indicates that miR-183-96-182 cluster could promote cell proliferation in various cancer types (Table [1](#T1){ref-type="table"}).

### miR-183-96-182 cluster inhibits cancer cell proliferation {#s3_1_2}

Interestingly, in certain cancers, over-expression of miR-183-96-182 cluster had an inhibitory effect on cell proliferation, a finding which is not consistent with the earlier reports related to most cancer types. The miR-96 target gene, ATG7, is a key factor in the autophagy pathway, which protects the cancer cells against stress responses such as hypoxia or starvation \[[@R87]\]. High-expression of miR-96 is thought to inhibit autophagy through directly targeting ATG7, and subsequently inhibit the survival of cancer cells under hypoxic conditions \[[@R23]\]. In addition, miR-96 is known to down-regulate RAD51 (a DNA repair protein) and REV1 (a DNA polymerase) to promote cellular sensitivity to cisplatin, which binds to and cause crosslinking of DNA to ultimately trigger apoptosis \[[@R36]\]. Similar results were also found for miR-182 in acute myelogenous leukemia \[[@R21]\]. Thus, the over-expression of miR-96/miR-182 appears to dramatically promote drug sensitization in cancer cells \[[@R36]\]. miR-96 was also shown to inhibit cell proliferation of ALK-expressing cancer cells *via* suppressing ALK expression, as well as those ALK-targeted genes, including AKT, STAT3, JNK and IGF-1 \[[@R88]\].

Notably, the inhibitory effect of miR-96 on pancreatic cancer cell proliferation has been clearly elucidated in the past few years \[[@R20], [@R51], [@R89], [@R90]\]. In pancreatic cancer, three important oncogenes, including KRAS \[[@R51]\], human either a go-go-related gene type 1 (HERG1) \[[@R89]\] and Glypican 1 (GPC1) \[[@R90]\], are known to be miR-96 target genes. KRAS, aberrantly activated in approximately 90% of pancreatic cancers \[[@R91]\], can promote abnormal cell proliferation by activating PI3K/Akt, NF-κB and ERK signaling pathways \[[@R92]--[@R95]\]. HERG1 is over-expressed in various cancer cells and found to promote cell proliferation \[[@R96]--[@R98]\]. GPC1 is exhibited high-expression in pancreatic cancers for efficient proliferation and angiogenesis \[[@R99]\]. miR-96 is known to target these three genes and, thereby, significantly increase the apoptosis rate in pancreatic cancer cells. However, the biological functions of miR-183 and miR-182 in pancreatic cancer are still unclear \[[@R80], [@R100]\]. Similar inhibitory effects were also observed in renal cell cancinoma and melanoma \[[@R52], [@R101], [@R102]\]. In contrast to the usual oncogenic function of the miR-183-96-182 cluster in most cancer types, the above tumor suppressor activity suggests a specific context (hypoxia/chemotherapy), phenotype, or cancer cell-dependent regulation of the miR-183-96-182 cluster in tumorigenesis.

### Contradictory results {#s3_1_3}

However the functions of miR-183-96-182 cluster in lung and gastric cancer are yet to be confirmed (Table [1](#T1){ref-type="table"}). In non-small cell lung cancer, miR-96 was shown to promote cell proliferation by targeting FOXO3 and RECK mRNA (A549, SK-MES-1, H1299 and SPC-A-1 cell lines) \[[@R61], [@R84]\], while according to a study by Vishwamitra *et al.*, miR-96 inhibits cell proliferation by targeting ALK (H2228 cell line) \[[@R88]\]. This reported discrepancy in results may be attributable to the inclusion of different cell types for analysis or involvement of different signaling pathways. Two studies on gastric carcinoma simultaneously reported contradictory results with respect to the function of miR-183 during cell proliferation in SGC-7901 cells \[[@R78], [@R103]\], Xu *et al*. found miR-183 was down-regulated in 65 gastric cancer tissue and 5 gastric cancer cell lines, miR-183 significantly inhibited SGC7901 and AGS cell viability with MTT assay. In contrast, Gu *et al*. found miR-183 was up-regulated in 80 tumor tissue, miR-183 significantly promoted SGC7901 cell proliferation by MTT and flow cytometry assay. These findings suggest that the regulation of cell proliferation by miR-183-96-182 cluster is a complicated synergic process, and the different functions of this cluster may be due to that the target genes might be expressed at different levels, contain mutations, or compete with other molecules. Other possible reasons for the contradictory results are summarized in Appendix 1-3.

miR-183-96-182 cluster in tumor invasion and metastasis {#s3_2}
-------------------------------------------------------

### miR-183-96-182 cluster promotes tumor invasion and metastasis {#s3_2_1}

It has been demonstrated that miR-183-96-182 cluster promotes tumor invasion and metastasis in most cancers, including thyroid, esophagus, gallbladder, ovary, bladder, kidney, liver cancers, melanoma, medulloblastoma, sarcoma, glioma, and myeloid cell tumor (Table [2](#T2){ref-type="table"}). miR-183 promotes tumor invasion and metastasis by targeting PDCD4, protein phosphatase 2A (PP2A), EGR1 and PTEN \[[@R76], [@R78], [@R104], [@R105]\]. In addition, TGF-β and Smad can also promote prostate cancer bone metastasis by induction of miR-96 and activation of the mTOR pathway \[[@R106]\]. Moreover, the inhibitory effect on metastasis in hepatoma carcinoma cells, induced by the suppression of miR-96 \[[@R107]\], was reported as being associated with the inhibition of EFNA5 expression by miR-96-targeting \[[@R85]\]. Similar findings have been reported in case of gastric, bladder, and breast cancers \[[@R3], [@R7], [@R83], [@R108]\]. With regard to miR-182, Huynh *et al.* reported significant suppression of invasive growth tendency and metastasis by suppressing miR-182 *in vivo* \[[@R109]\]. Moreover, similar to the effects of TGF-β on miR-96, TGF-β up-regulates miR-182, which can target CYLD and thus promote the activation of NF-κB in gliomablastoma. Therefore, TGF-β-mediated up-regulation of miR-182 probably results in the persistent activation of NF-κB in gliomblastoma, which subsequently leads to angiogenesis and tumor invasion. Table [2](#T2){ref-type="table"} shows the target genes of miR-183-96-182 cluster which regulate invasion and metastasis in various tumor cells.

###### miR-183-96-182 cluster in tumor invasion, migration, and metastasis

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Member of miR-183-96-182 cluster   Oncogene/Tumor suppressor   Target genes                       Cell lines                                                                                                  Cancer types                                    Results
  ---------------------------------- --------------------------- ---------------------------------- ----------------------------------------------------------------------------------------------------------- ----------------------------------------------- ---------------------------------------------------------
  miR-183-96-182                     Oncogene                    RAB21(miR-183)\                    MCF-7, T47D                                                                                                 Breast cancer\*                                 Promote migration \[[@R3]\].
                                                                 RAB40B(miR-96 and miR-183)\                                                                                                                                                                    
                                                                 TNFSF11(miR-96)                                                                                                                                                                                

  miR-183-96-182                     Oncogene                    BRMS1L                             MCF-7, T47D, MDA-MB-435s, MDA-MB-468                                                                        Breast cancer\*                                 Promote EMT and invasion \[[@R15]\].

  miR-183-96-182                     Oncogene                    \--                                R262, R300 UW402, UW426, D341, D384, D425, D458, D556, D283, DAOY                                           Medulloblastoma                                 Promote migration \[[@R155]\].

  miR-183-96-182                     Oncogene                    FOXO1                              Hep3B, SNU387, HKCI-1, HKCI-8                                                                               Hepatocellular carcinoma                        Promote migration \[[@R13]\].

  miR-183-96-182                     Tumor suppressor            FOXF2                              55 human NSCLC cell lines                                                                                   Lung cancer                                     Inhibit invasion and metastasis \[[@R116]\].

  miR-183, miR −96                   Tumor suppressor            SLUG, ZEB1, ITGB1, and KLF4        HCT116, MCF10A                                                                                              Colon cancer\*\*\*                              Inhibit EMT, migration, and invasion \[[@R9]\].

  miR-96, miR-182                    Oncogene                    EFNA5                              HepG2, Hep3B, Huh7, SK-Hep1                                                                                 Hepatocellular carcinoma                        Promote invasion \[[@R85]\].

  miR-183                            Oncogene                    \--                                HTori-3, FTC-133                                                                                            Follicular thyroid carcinomas                   Promote migration \[[@R171]\].

  miR-183                            Oncogene                    PDCD4                              Eca109, TE13                                                                                                Esophageal cancer                               Promote invasion \[[@R76]\].

  miR-183                            Oncogene                    PDCD4                              SGC-7901                                                                                                    Gastric cancer\*\*                              Promote invasion \[[@R78]\].

  miR-183                            Oncogene                    PDCD4                              SW1990                                                                                                      Pancreatic cancer                               Promote invasion and migration \[[@R80]\].

  miR-183                            Oncogene                    SOCS-6                             PANC-1                                                                                                      Pancreatic cancer                               Promote invasion and metastasis \[[@R157]\].

  miR-183                            Oncogene                    SOCS-6                             HepG2, Hep3B                                                                                                Hepatocellular carcinoma                        Promote invasion \[[@R158]\].

  miR-183                            Oncogene                    PP2A-Cα, PP2A-Cβ, and PP2A-B56-γ   ACHN, A498                                                                                                  Renal cancer                                    Promote migration and invasion \[[@R104]\].

  miR-183                            Oncogene                    EGR1 and PTEN                      SYO-1, FUJI, HCT116, DLD1, Rh30, JR1                                                                        Synovial sarcoma, RMS, and colon\*\*\* cancer   Promote migration \[[@R105]\].

  miR-183                            Oncogene                    NEFL                               U251                                                                                                        Glioma                                          Promote invasion \[[@R156]\].

  miR-183                            Tumor suppressor            TIAM1                              SKOV-3ip, HO-8910PM                                                                                         Ovarian cancer                                  Inhibit migration and invasion \[[@R124]\].

  miR-183                            Tumor suppressor            BMI1                               AGS, SGC7901, MKN28, MGC803, HGC27                                                                          Gastric cancer\*\*                              Inhibit invasion \[[@R103]\].

  miR-183                            Tumor suppressor            EZR                                MGC-803, SGC-7901, BGC-823, MKN-45, MKN-28                                                                  Gastric cancer\*\*                              Inhibit invasion \[[@R120]\].

  miR-183                            Tumor suppressor            EZR                                SOSP-9607, and MG63, U2OS, Saos2, HOS, SV40                                                                 Osteosarcoma                                    Inhibit migration and invasion \[[@R118], [@R119]\].

  miR-183                            Tumor suppressor            EZR                                MDA-MB-231, T47D, SKBR-3, ZR-75-1                                                                           Breast cancer\*                                 Inhibit migration \[[@R121]\].

  miR-183                            Tumor suppressor            EZR                                801D, 95C                                                                                                   Lung cancer                                     Inhibit migration \[[@R122]\].

  miR-183                            Tumor suppressor            MMP-9                              Siha, HeLa                                                                                                  Cervical carcinoma                              Inhibit invasion and metastasis \[[@R172]\].

  miR-183                            Tumor suppressor            ITGB1 and KIF2A                    HeLa                                                                                                        Cervical carcinoma                              Inhibit migration and invasion \[[@R125]\].

  miR-96                             Oncogene                    RECK                               MDA-MB-231, MCF-7, MDA-MB-468, MDA-MB-435, T-74D, MDA-MB-453                                                Breast cancer                                   Promote invasion \[[@R83]\].

  miR-96                             Oncogene                    MAP4K1 and IRS1                    T24                                                                                                         Bladder cancer                                  Promote invasion \[[@R108]\].

  miR-96                             Oncogene                    \--                                AGS                                                                                                         Gastric cancer                                  Promote invasion \[[@R7]\].

  miR-96                             Oncogene                    \--                                HCCLM6                                                                                                      Hepatocellular carcinoma                        Promote invasion \[[@R107]\].

  miR-96                             Oncogene                    AKT1S1                             DU145, PC3, LNCap, 22Rv1, RasB1, AC1, AC3                                                                   Prostate cancer                                 Promote bone metastasis \[[@R106]\].

  miR-96                             Tumor suppressor            KRAS                               HPDE, BxPC-3, PK-8, and MIA PaCa-2, PANC-1, BxPC-3                                                          Pancreatic cancer                               Inhibit migration and invasion \[[@R20], [@R51]\].

  miR-182                            Oncogene                    MTSS1                              HLE, HLF, HepG2, Hep3B, HUH-1                                                                               Hepatocellular carcinoma                        Promote invasion \[[@R173]\].

  miR-182                            Oncogene                    CYLD                               LN382T, A172, T98G, LN18, LN229, LN464, SNB19, U373MG, U87MG, LN444, LN443, LN428, U118MG, LN-Z308, LN319   Glioma                                          Promote invasion \[[@R8]\].

  miR-182                            Oncogene                    RECK                               MCF-7, MDA-MB-231, SKBR3, BT-20                                                                             Breast cancer                                   Promote tumorigenicity and invasion \[[@R12]\].

  miR-182                            Oncogene                    MIM                                4T1 series, MCF10 series                                                                                    Breast cancer                                   Promote invasion and metastasis \[[@R174]\].

  miR-182                            Oncogene                    PFN1                               MDA-MB-231                                                                                                  Breast cancer                                   Promote invasion \[[@R168]\].

  miR-182                            Oncogene                    \--                                DAOY, D458 Med, Med8A                                                                                       Medulloblastoma                                 Promote migration \[[@R175]\].

  miR-182                            Oncogene                    RSU1, MTSS1, PAI1, and TIMP1       STS-48, STS-109, STS-145, primary mice sarcomas cell lines (Kras and p53 mutation)                          Sarcomas                                        Promote migration, invasion and metastasis \[[@R176]\].

  miR-182                            Oncogene                    \--                                Primary mice sarcomas cell lines                                                                            Sarcomas                                        Promote metastasis \[[@R18]\].

  miR-182                            Oncogene                    CHL1                               TPC-1, BCPAP                                                                                                Papillary thyroid carcinoma                     Promote invasion \[[@R161]\].

  miR-182                            Oncogene                    SATB2                              DLD-1, HCT116, SW480, SW620, Lovo                                                                           Colorectal cancer                               Promote migration, invasion and metastasis \[[@R162]\].

  miR-182                            Oncogene                    FOXF2                              HT29, SW480, SW620, HCT116                                                                                  Colorectal cancer                               Promote invasion \[[@R71]\].

  miR-182                            Oncogene                    TSP-1                              HCT-116, HT-29                                                                                              Colon cancer                                    Promote metastasis \[[@R177]\].

  miR-182                            Oncogene                    PDCD4                              A549                                                                                                        Lung cancer\*\*\*\*                             Promote invasion \[[@R56]\].

  miR-182                            Oncogene                    PDCD4                              OVCAR3, SKOV3, OV2008, HEY, 3AO, A2780, HO8910, C13                                                         Ovarian cancer                                  Promote invasion \[[@R77]\].

  miR-182                            Oncogene                    BRCA1, MTSS1, and HMGA2            SKOV3, HEY, OVCAR-3                                                                                         Ovarian cancer                                  Promote invasion and metastasis \[[@R178]\].

  miR-182                            Oncogene                    MITF and FOXO3                     SK-MEL-19, -29, -85, -94, -100, -103, -147, -173, -187, -192, -197. 501mel, B16F10, WM35                    Melanoma                                        Promote migration, invasion and metastasis \[[@R35]\].

  miR-182                            Oncogene                    \--                                \--                                                                                                         Melanoma                                        Promote metastasis \[[@R109]\]

  miR-182                            Oncogene                    CADM1                              GBC-SD                                                                                                      Gallbladder cancer                              Promote migration, invasion and metastasis \[[@R11]\].

  miR-182                            Oncogene                    NDRG1                              LNCap, PC-3, DU145, 22Rv1                                                                                   Prostate cancer\*\*\*\*\*                       Promote invasion \[[@R126]\].

  miR-182                            Oncogene                    FOXF2, RECK and MTSS1              LNCaP, PC-3, DU145                                                                                          Prostate cancer\*\*\*\*\*                       Promote invasion \[[@R72]\].

  miR-182                            Oncogene                    RECK and SMAD4                     J82, T24, UM-UC-3                                                                                           Bladder cancer                                  Promote invasion and metastasis \[[@R169]\].

  miR-182                            Tumor suppressor            FOXO3                              A549, H1299, CL 1-0, CL 1-5                                                                                 Lung cancer\*\*\*\*                             Inhibit migration and invasion \[[@R16]\].

  miR-182                            Tumor suppressor            GNA13                              PC3, LNCaP                                                                                                  Prostate cancer\*\*\*\*\*                       Inhibit invasion \[[@R123]\].
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Contradictory findings were marked as the same number of \*.

Abbreviations: AKT1S1: AKT1 substrate 1; BMI1: BMI1 proto-oncogene; BRCA1: Breast cancer 1, early onset; BRMS1L: Breast Cancer Metastasis Suppressor 1-like; CADM1: Cell adhesion molecule 1; CHL1: Cell adhesion molecule L1-like; CYLD: Cylindromatosis; EGR1: Early growth response 1; EZR: Ezrin; FOXO: Forkhead box O; FOXF2: Forkhead box F2; GNA13: G-protein subunit α-13; HMGA2: High mobility group AT-hook 2; IRS1: Insulin receptor substrate 1; ITGB1: Integrin, beta 1; KIF2A: Kinesin heavy chain member 2A; KLF4: Kruppel-like factor 4; KRAS: Kirsten rat sarcoma viral oncogene homolog; MAP4K1: Mitogen-activated protein kinase kinase kinase kinase 1; MIM: Missing in Metastasis; MMP-9: Matrix metallopeptidase 9; MITF: Microphthalmia-associated transcription factor-M; MTSS1: Metastasis suppressor 1; NDRG1: N-myc downstream regulated 1; PDCD4: Programmed cell death 4; PFN1: profilin 1; PP2A: Protein phosphatase 2A; PTEN:Phosphatase and tensin homolog; RECK: Reversion-inducing-cysteine-rich protein with kazal motifs; PAI1:; Plasminogen activator inhibitor-1; RSU1: Ras suppressor protein 1; SATB2: SATB homeobox 2; SLUG: Snail family zinc finger 2; SMAD4: SMAD family member 4; SOCS-6: Suppressor of cytokine signaling 6; TIAM1: T-cell lymphoma invasion and metastasis 1; TIMP1: Tissue inhibitor of metalloproteinases 1; TSP-1: Thrombospondin-1; ZEB1: Zinc finger E-box binding homeobox 1

### miR-183-96-182 cluster inhibits tumor invasion and metastasis {#s3_2_2}

On the contrary, miR-183-96-182 suppresses tumor metastasis in lung, colon, and pancreatic cancers (Table [2](#T2){ref-type="table"}). Transcriptional repressor Zin C finger E-box-binding homeobox 1 (ZEB1) family is a series of transcription factors which contain zinc finger domain. The highly conserved zinc finger structure can bind to E-box domain of the promoter of target genes, such as E-cadherin, the key epithelial marker for epithelial-mesenchymal transition (EMT and MET) \[[@R110], [@R111]\]. A recent study indicated a ZEB1/miR-200 double negative feedback loop in EMT at different stages of tumor development \[[@R112]\]. Notably, miR-183/96 can inhibit EMT *via* suppressing ZEB1 expression. Besides, ZEB1 can also block the transcription of miR-183-96-182 cluster by binding to its promoter \[[@R9]\]. miR-183-96-182 cluster and ZEB1 exert a double negative feedback loop in p21−/− cells. However, more recently, p21, an inhibitor of cyclin-dependent kinase through suppressing the expressions of CDK1 and CDK1 proteins \[[@R113]\], can also inhibit EMT progression \[[@R114], [@R115]\]. There is further evidence that p21 can interact with ZEB1 to form a complex and binds to the promoter of miR-183-96-182 cluster, which suppresses the transcription inhibition by ZEB1 and results in the suppression of EMT. The schematic diagram is provided in Appendix 1-4. Similar results were also reported in lung cancer cells by Kundu *et al.*, where they found that FOXF2 correlates with ZEB1 expression, and miR-183-96-182 can suppress FOXF2 to inhibit tumor invasion and metastasis in lung cancers \[[@R116]\].

The EZR gene, the target gene of miR-183, plays an important role in angiogenesis and tumor metastasis in various tumors \[[@R117]\]. The miR-183 was found to block MAPK/ERK signaling pathway, as well as inhibit tumor invasion and metastasis by suppressing EZR expression in gastric, breast, lung cancers, and osteosarcoma \[[@R118]--[@R122]\]. Additionally, several previous studies demonstrated that some oncogenes, including TIAM1, BMI1, TSP-1, FOXO3, GNA13, ITGB1, KIF2A, SLUG, ITGB1, and KLF4, were targeted by miR-183 and miR-96 for the suppression of invasion and metastasis in oophoroma, lung, prostate, colon, cervix, stomach and pancreas cancer cells \[[@R9], [@R16], [@R20], [@R51], [@R103], [@R123]--[@R125]\] (Table [2](#T2){ref-type="table"}).

### Contradictory results {#s3_2_3}

Investigations of the effects of miR-183-96-182 cluster on tumor invasion and metastasis have sometimes yielded contradictory results in different tumors, and in some cases, even within the same tumor type. miR-183 was found to be down-regulated by Cao *et al*. (in 52 pairs of FFPE samples and 5 cell lines) and Xu *et al*. (in 65 pairs of samples and 5 cell lines) (Table [2](#T2){ref-type="table"}) and hypothesized to inhibit tumor invasion by suppressing the expressions of BMI1 or EZR proteins in gastric cancers \[[@R103], [@R120]\]. Conversely, Hu *et al.* reported that miR-183 was up-regulated (20 non-tumor tissue and 80 tumor tissue samples) and promotes gastric cancer cell invasion by inhibiting PDCD4 expression \[[@R78]\]. Similar differences in results were also reported in case of prostate cancers. miR-182 was over-expressed in prostate cancer tissue by Hirata *et al*. (52 paired samples) and Liu *et al*. (5 tumor and 3 non-tumor tissue) and enhanced the invasive and migratory capacity in PC3 and DU145 cells by targeting NDRG1, FOXF2, RECK, and MTSS1 genes \[[@R72], [@R126]\]. In contrast, over-expression of miR-182 was shown to inhibit tumor invasion in PC3 and LNCaP cells by suppressing GNA13 expression \[[@R123]\]. These findings suggest a context-dependent phenotype for the miR-183-96-182 cluster in carcinogenesis which needs to be further investigated to understand the complex interactions, especially in those cancers where contradictory results have been observed, such as prostate, colon, lung, breast, and gastric cancers (Table [2](#T2){ref-type="table"}).

miR-183-96-182 cluster in cancer prognosis {#s3_3}
------------------------------------------

Most of cancer cells display high-expression of miR-183 \[[@R127], [@R128]\]. The up-regulation of miR-183 is known to be associated with poor prognosis in breast cancer, colorectal cancer, hepatocellular cancer, and prostate cancer \[[@R13], [@R129]--[@R134]\], while predicts a good prognosis in osteosarcoma \[[@R135]\] (Table [3](#T3){ref-type="table"}). This finding is consistent with its functions in cell proliferation, invasion and metastasis in these tumors types. Notably, miR-183 might affect the prediction for PSA-dependent diagnosis and prognosis *via* regulating PSA expression \[[@R136]\]. With respect to the prediction of miR-183-related prognosis, the available evidence from different studies is contradictory in lung cancer. Lin *et al.* showed the low expression of miR-183 in the peripheral blood which was associated with increased TNM stage in lung cancer patients (13 squamous-cell carcinoma and 17 adenocarcinoma) \[[@R137]\]. While Zhu *et al.* demonstrated the up-regulation of miR-183 family in lung cancer tissue (36 squamous-cell carcinoma and 34 adenocarcinoma), and that it appeared to confer a poor prognosis \[[@R48]\]. The wide variability in the reported results may be attributable to the differences between blood and tissue or the heterogeneity in lung cancer cells.

###### miR-183-96-182 cluster for prediction of cancer prognosis

  Member of miR-183-96-182 cluster   Oncogene/Tumor suppressor   Cancer types                                 Target genes                                            Results
  ---------------------------------- --------------------------- -------------------------------------------- ------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------
  miR-183-96-182                     Oncogene                    Hepatocellular carcinoma (tissue)            FOXO1                                                   Associated with prognosis (microvascular invasion, tumor differentiation, and patients survival) \[[@R13]\].
  miR-183-96-182                     Oncogene                    Lung cancer (tissue and serum)               \--                                                     Associated with prognosis (survival) \[[@R48]\].
  miR-183, miR-96                    Oncogene                    Prostate cancer (tissue)                     \--                                                     Associated with prognosis (tumor aggressiveness, metastatic and overall survival) when combined with other microRNAs \[[@R131]\].
  miR-183                            Oncogene                    Lung cancer (tissue)\*                       \--                                                     Associated with prognosis (lymph node metastasis, clinical stage and EGFR mutation and patients survival) \[[@R179]\].
  miR-183                            Oncogene                    Breast cancer (tissue)                       \--                                                     Associated with prognosis (TNM clinical stage) \[[@R129]\].
  miR-183                            Oncogene                    Colorectal cancer (plasma)                   \--                                                     Associated with cancer recurrence and prognosis (lymph node metastasis, distant metastasis, TNM stage) \[[@R132]\].
  miR-183                            Oncogene                    Colorectal cancer (tissue)                   \--                                                     Associated with prognosis (clinical stage, lymph node metastasis, distant metastasis and patients survival) \[[@R133]\].
  miR-183                            Oncogene                    Hepatocellular carcinoma (tissue)            \--                                                     Associated with cancer progression (TNM stage and cirrhosis), but not with patient survival \[[@R130]\].
  miR-183                            Oncogene                    Hepatocellular carcinoma (serum)             \--                                                     Associated with prognosis (TNM stage and postoperative survival) \[[@R180]\].
  miR-183                            Tumor suppressor            Lung cancer (serum) \*                       \--                                                     Associated with prognosis (metastasis) \[[@R137]\].
  miR-183                            Tumor suppressor            Osteosarcoma (tissue)                        EZR                                                     Associated with aggressiveness and poor prognosis (tumor grade, response to chemotherapy, metastasis and recurrence) \[[@R135]\].
  miR-183                            \-                          Prostate cancer (cancer cell)                KLK3/PSA                                                miR-183 binds to the 3′ UTR of PSA and increases its protein and mRNA levels \[[@R136]\].
  miR-96                             Oncogene                    Prostate cancer (tissue)                     \--                                                     Associated with prognosis (tumor stage, recurrence and survival) \[[@R138]\].
  miR-96                             Oncogene                    Prostate cancer (tissue)                     \--                                                     Not correlates with prognosis (biochemical recurrence and clinicopathological parameters) \[[@R139]\].
  miR-96                             Oncogene                    Hepatocellular carcinoma (tissue)            LRP6, FOXO1A, and MAP2K1 (Not biologically validated)   Associated with prognosis (recurrence) when combined with other microRNAs \[[@R140]\].
  miR-96                             Oncogene                    Colorectal cancer (tissue) \*\*              \--                                                     Associated with prognosis (overall survival)\[[@R32]\]
  miR-96                             Tumor suppressor            Colorectal cancer (plasma) \*\*              KRAS                                                    Associated with prognosis (distant metastasis and survival) \[[@R181]\].
  miR-96                                                         Acute myeloid leukemia (mononuclear cells)   \--                                                     Associated with prognosis (relapse-free survival and overall survival) \[[@R141]\].
  miR-182                            Oncogene                    Nasopharyngeal carcinoma (tissue)            \--                                                     Associated with prognosis (overall survival, disease-free survival, and distant metastasis) \[[@R144]\].
  miR-182                            Oncogene                    Pancreatic cancer (plasma)                   \--                                                     Associated with prognosis (Clinical stages, lymph node metastasis and survival) \[[@R143]\].
  miR-182                            Oncogene                    Breast cancer (tissue)                       \--                                                     Associated with prognosis (lymph node metastases and grade III occurrence) \[[@R142]\].
  miR-182                            Oncogene                    Colon cancer (tissue)                        FBXW7                                                   Associated with prognosis (Survival) \[[@R145]\].
  miR-182                            Oncogene                    Colorectal cancer (tissue)                   \--                                                     Associated with prognosis (T-stage, lymph node metastasis, distant metastasis, Dukes\' stage, and survival) \[[@R146]\].
  miR-182                            Oncogene                    Colorectal cancer (tissue)                   \--                                                     Associated with prognosis (TNM stage, lymph node metastasis, and survival) \[[@R147], [@R148]\].
  miR-182                            Oncogene                    Prostate cancer (tissue)                     \--                                                     Associated with prognosis (T stages, Gleason score, TMPRSS2-ERG status, and patient survival) \[[@R149]\].
  miR-182                            Oncogene                    Bladder cancer (tissue)                      \--                                                     Associated with prognosis (aggressiveness and survival) \[[@R150]\].
  miR-182                            Oncogene                    Glioma (tissue)                              \--                                                     Associated with prognosis (overall survival) \[[@R151]\].
  miR-182                            Tumor suppressor            Lung cancer (tissue)                         \--                                                     Associated with prognosis (disease-specific survival) \[[@R152]\].

Contradictory findings were marked as the same number of \*.

Abbreviations: EZR: Ezrin; FBXW7: F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase; FOXO1A: Forkhead box O1a; KLK3/PSA: Kallikrein-related peptidase 3; KRAS: Kirsten rat sarcoma viral oncogene homolog; LRP6: Low density lipoprotein receptor-related protein 6; MAP2K1: Mitogen-activated protein kinase kinase 1

The high expression of miR-96 in prostate cancer is well documented \[[@R23], [@R41], [@R63], [@R66], [@R67], [@R138]\]. Larne *et al.* recently reported a miRNA index quote (miQ) in prostate cancer, which uses four miRNAs (miR-96, 183, 145, and 221) for more accurate diagnosis (area under the curve, AUC = 0.931) and prognosis (AUC = 0.895 for predicting aggressiveness and AUC = 0.827 for metastasis). miQ was verified in an independent Dutch cohort and three external cohorts, and significantly outperformed the prostate-specific antigen \[[@R131]\]. Schaefer *et al*. demonstrated that highly expressed miR-96 can predict cancer recurrence after radical prostatectomy \[[@R138]\]. Additionally, Haflidadottir *et al*. found miR-96 expression correlated with WHO grade, and the overall survival time in prostate cancer \[[@R67]\]. In contrast, a recent investigation found no significant correlation between the expression of miR-96 and clinicopathological parameters \[[@R139]\]. Thus, suggesting that more studies are required to understand the prognostic relevance of miR-96. In addition, miR-96 was reported as a potential biomarker for the predicting recurrence after surgical resection of hepatocellular cancer \[[@R140]\], and as prognostic indicator in lung cancer, colorectal cancer and acute myeloid leukemia \[[@R32], [@R48], [@R141]\] (Table [3](#T3){ref-type="table"}).

Corresponding to the biological functions of miR-182 in various tumors, the up-regulation of miR-182 was associated with poor prognoses in hepatocellular carcinoma \[[@R13]\], breast cancer \[[@R142]\], pancreatic cancer \[[@R143]\], oropharyngeal carcinoma \[[@R144]\], colorectal adenocarcinoma \[[@R145]--[@R148]\], prostate cancer \[[@R149]\], bladder cancer \[[@R150]\], and glioblastoma \[[@R151]\] (Table [3](#T3){ref-type="table"}). In contrast, the up-regulation of miR-182 was found to correlate with good prognosis in lung cancer \[[@R152]\]. We presume that this might be associated with the miR-183 target genes, such as RGS17, RASA1, CTTN, and FOXO3, which have been shown to inhibit cell proliferation, tumor invasion and metastasis in lung cancer cells \[[@R16], [@R57], [@R58], [@R153]\].

CONCLUDING REMARKS {#s4}
==================

Recent studies suggest an important role of miR-183-96-182 cluster in tumorigenesis, cancer progression, tumor invasion and metastasis. Although most of the reports showed that miR-183-96-182 cluster is an oncogene cluster, it also functions as a TSG by inhibiting cell proliferation and metastasis in certain cancer cells. We hypothesize that the different results observed in expression and function of the miR-183-96-182 cluster may result from different underlying tissue types, different expression abundance of miR-183-96-182 or their target genes, differences between cell lines (Table [1](#T1){ref-type="table"}--[2](#T2){ref-type="table"}), differences between cell line and tumor tissue, tissue and blood (Table [3](#T3){ref-type="table"}), and differences between detecting methods used. Recent studies have also indicated diagnostic and prognostic relevance of the members of miR-183-96-182 cluster, either independently or collectively. These new data on the functions of miR-183-96-182 cluster in various tumors suggest that further studies will be needed to clarify its functions in the various stages and histological subtypes in different types of tumors, which will significantly improve the accuracy of the prediction for tumor diagnosis or prognosis. As regards the conflicting results in certain tumors, we believe that miR-183-96-182 cluster might play different roles because of tumor heterogeneity, which will be important for the individual diagnosis and prognosis in anti-tumor treatment.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================
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miRNA

:   microRNA

TSS

:   transcriptional start site

TSG

:   tumor suppressor gene

EMT

:   epithelial-mesenchymal transition.
